Artivion AORT 深 沪
等待开盘 08-21 09:30:00 美东时间
27.96
-0.860
-2.98%
华盛通- 最 高29.01
- 今 开28.755
- 成交量 62.86万股
- 最 低 27.77
- 昨 收 28.82
- 总市值 13.63亿
- 52周最高 48.25
- 市盈率 静 135.14
- 换手率 1.29%
- 52周最低 19.16
- 委 比 33.33%
- 总股本 4875.62万
- 历史最高 48.25
- 量 比 0.86
- 振 幅 4.30%
- 历史最低 3.82
- 每 手 1
- 风险率 8.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40
Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $39 to $40.
08-18 21:37
Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.
08-07 04:27
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two ...
07-29 04:10
Next Century Growth Investors exits Bloom Energy, Coherent; adds DigitalOcean in Q2
In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE), IPG Photonics Corporation (IPGP),...
07-24 23:00
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Needham Reiterates Buy on Artivion, Maintains $44 Price Target
Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $44 price target.
07-20 18:12
Artivion Says FDA Approves Premarket Approval Application For AMDS Hybrid Prosthesis
Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type...
06-29 19:13
Artivion Completes Acquisition of Endospan Ltd.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long...
05-18 19:00
